ArticleCureus2026
Gilteritinib-Associated Hypertriglyceridemia During Acute Myeloid Leukemia Triplet Therapy in a 52-Year-Old Man: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) harboring a FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is characterized by a more aggressive clinical course, a higher likelihood of disease recurrence, and inferior survival outcomes. The introduction of targeted agents such as gilteritinib has expanded therapeutic options for patients with FLT3-mutated AML; however, the spectrum of rare treatment-related toxicities remains incompletely defined. We describe a case of profound hypertriglyceridemia that developed during treatment with a combination of azacitidine, venetoclax, and gilteritinib. A 52-year-old man presented with constitutional symptoms, marked leukocytosis, splenomegaly, and bone marrow findings consistent with AML exhibiting monocytic differentiation. Molecular analysis identified coexisting FLT3-ITD, nucleophosmin 1 (NPM1), and DNA methyltransferase 3A (DNMT3A) mutations. Owing to concomitant fungal pneumonia and unsuitability for intensive induction chemotherapy, he was treated with a modified regimen comprising azacitidine, venetoclax, and gilteritinib. The patient's baseline lipid profile was within normal limits. Following two cycles of induction therapy, a bone marrow aspirate was done. Serum triglyceride levels were found to be severely elevated at 6,964 mg/dL. Given the patient's prior episode of pancreatitis, this abnormality was considered clinically significant. Gilteritinib, venetoclax, and isavuconazole were discontinued, and lipid-lowering therapy with rosuvastatin and fenofibrate was commenced. Triglyceride concentrations progressively declined and returned to near-normal levels within one month. This report draws attention to a potentially serious and insufficiently recognized metabolic complication associated with FLT3 inhibitor-based combination therapy. It also underscores the importance of routine lipid surveillance, particularly in patients receiving concomitant azole antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.